Clinical trials
Lupus Nephritis clinical trials
Below are recruiting lupus nephritis clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06925542RecruitingPhase 1
Study of CTX112 for adults with autoimmune disease
This trial tests an experimental cell therapy called CTX112 for people with lupus, scleroderma, or inflammatory myositis that hasn't responded well to standard treatments. The goal is to see if it's safe and if it can help control the disease.
La Jolla, CaliforniaAges 18–70 - NCT06277427Recruiting
CAR-T cell therapy for refractory vasculitis and lupus nephritis
This trial tests a new type of cell therapy called CAR-T cells that target BCMA (a protein on certain immune cells) for people with two autoimmune diseases: ANCA-associated vasculitis and lupus nephritis. It is for patients whose disease has not responded to standard treatments or has come back after initial improvement.
Wuhan, HubeiAges 18–70 - NCT05039619RecruitingPhase 2
Obinutuzumab trial for adolescents with active lupus kidney inflammation
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
Loma Linda, CaliforniaAges 5–17 - NCT06350110RecruitingPhase 1/Phase 2
CAR T cells for lupus
This trial tests a new type of CAR T cell therapy for people with active lupus that has not responded to other treatments. It uses specially engineered cells to target and eliminate certain immune cells that are causing the disease, with the goal of reducing symptoms and preventing flare-ups.
Beijing, Beijing MunicipalityAges 18–90 - NCT06217107Recruiting
Wellness and work support for lupus and lupus nephritis
This study tests a wellness and work support program for women with lupus or lupus nephritis. The goal is to help you manage your health and connect with others through an online program.
Atlanta, GeorgiaAges 18 years+ - NCT06839976RecruitingPhase 1/Phase 2
CART19 cell therapy for lupus
This trial tests a treatment called CART19, where your own immune cells are modified in a lab to target and destroy faulty B cells that cause lupus inflammation. It's for young people with active lupus that hasn't improved with standard treatments.
Philadelphia, PennsylvaniaAges 10–29 - NCT06585514RecruitingPhase 1/Phase 2
CAR T-cell therapy for hard-to-treat lupus
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
Beijing, Beijing MunicipalityAges 3–65 - NCT07666711Recruiting
Kidney biomarker study for lupus patients
This study aims to find better ways to detect kidney problems in people with lupus by testing blood and urine samples. If you have lupus, you may help researchers improve how kidney disease is diagnosed and monitored.
Oslo, OsloAges 18 years+ - NCT06708845RecruitingPhase 1
Zamto-cel cell therapy for autoimmune diseases
This early-phase trial tests a new cell therapy called Zamto-cel for people with lupus (with or without kidney inflammation) or systemic sclerosis (hardening of the skin and internal organs). It is for those whose condition has not improved enough after standard treatments.
Milwaukee, WisconsinAges 18 years+ - NCT06902844Recruiting
Eque-cel for lupus that has not responded to other treatments
This trial tests a new cell therapy called eque-cel for people with lupus that has come back or is not controlled by standard treatments. It aims to see if this therapy can reduce lupus activity and improve symptoms.
Wuhan, HubeiAges 18 years+ - NCT05443516Recruiting
Blood and urine markers in active lupus kidney disease
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
BrusselsAges 18–70 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07038447Enrolling by invitationPhase 1
A study of KITE-363 for people with severe autoimmune diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune diseases (like lupus, scleroderma, or inflammatory myositis) that haven't improved with standard treatments. The goal is to see if KITE-363 can reduce disease activity and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT06308978RecruitingPhase 1
Study of FT819 for B-cell autoimmune diseases
This trial tests a new cell therapy, FT819, for people with certain autoimmune diseases like lupus, vasculitis, myositis, or scleroderma that haven't improved with at least two previous treatments. The goal is to see if it can help control the disease.
Beverly Hills, CaliforniaAges 12–70 - NCT07225387RecruitingPhase 4
Belimumab and voclosporin for lupus kidney disease
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
Glendale, ArizonaAges 18–80 - NCT06375993Enrolling by invitationPhase 1
Prula-cel for autoimmune diseases: a phase 1 study
This trial tests a new treatment called prulacabtagene leucel (prula-cel), which is a type of immune cell therapy (CAR T-cells) for people with certain autoimmune diseases. It aims to see if it can reset the immune system and reduce disease activity in conditions like lupus, scleroderma, vasculitis, or myositis.
Redwood City, CaliforniaAges 18–80 - NCT03929887Recruiting
Kidney biopsy patients join a kidney tissue research bank
This study builds a kidney tissue “library” to help researchers analyze kidney disease in newer ways. It may help by improving how glomerular (kidney filter) diseases are understood over time, using samples from people who already had a biopsy.
ChuncheonAges Any age - NCT07403188Recruiting
Long-Term Follow-Up Study for KYV-101 Participants
This long-term follow-up study checks on the health and safety of people who have already received the experimental cell therapy KYV-101 in a previous clinical trial. It is a way for them to be monitored over time without any additional treatments.
Denver, ColoradoAges 18 years+ - NCT07363460RecruitingPhase 2
HSK39297 tablets for active lupus nephritis
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
Nanjing, JiangsuAges 18–75 - NCT01802034Recruiting
Study kidney samples to understand autoimmune, inflammatory, and diabetic disease
This trial collects and studies kidney tissue samples to better understand what drives kidney problems linked to autoimmune, inflammation, and diabetes. Your participation may help researchers develop better ways to diagnose and treat these conditions.
New York, New YorkAges 18 years+ - NCT07053891Recruiting
Safety survey of LUPKYNIS for lupus nephritis
This study is a safety survey for people who are just starting to take LUPKYNIS for lupus nephritis, a type of kidney inflammation caused by lupus. It aims to collect information on how well the drug works and any side effects in real-world use.
Osaka, OsakaAges 15 years+ - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus nephritis?
- Yes. Clin2 currently lists 79 recruiting lupus nephritis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus nephritis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus nephritis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.